![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon alfa-2a (40KD), and ribavirin with or without mericitabine in HCV genotype 1-infected treatment-experienced patients with advanced hepatic fibrosis: the MATTERHORN study
|
|
|
Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
I.M. Jacobson, D.M. Jensen, S. Pol, G.R. Foster, J.J. Feld, E. Yoshida, M. Jablkowski, H. Perez-Gomez, S. Shahdad, R. Kulkarni, M.T. Navarro, A. Scalori, J.A. Tavel, G. Hooper, N.S. Shulman, E.S. Yetzer
![AASLD1.gif](../images/111312/111312-13/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-13/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-13/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-13/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-13/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-13/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-13/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-13/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-13/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-13/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|